Thermo Fisher Scientific Inc. (NYSE:TMO) Stake Lowered by Albion Financial Group UT

Albion Financial Group UT decreased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 25,684 shares of the medical research company’s stock after selling 378 shares during the quarter. Albion Financial Group UT’s holdings in Thermo Fisher Scientific were worth $13,362,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of the company. Advisory Alpha LLC lifted its holdings in Thermo Fisher Scientific by 12.5% in the fourth quarter. Advisory Alpha LLC now owns 1,432 shares of the medical research company’s stock worth $745,000 after purchasing an additional 159 shares during the period. Missouri Trust & Investment Co bought a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $29,000. Eads & Heald Wealth Management raised its holdings in Thermo Fisher Scientific by 0.8% during the fourth quarter. Eads & Heald Wealth Management now owns 4,512 shares of the medical research company’s stock worth $2,347,000 after purchasing an additional 37 shares in the last quarter. Barlow Wealth Partners Inc. acquired a new position in shares of Thermo Fisher Scientific during the 4th quarter valued at $210,000. Finally, XML Financial LLC grew its holdings in Thermo Fisher Scientific by 49.6% during the fourth quarter. XML Financial LLC now owns 863 shares of the medical research company’s stock worth $449,000 after acquiring an additional 286 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Buying and Selling

In related news, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction dated Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $168,048.00. Following the transaction, the executive vice president now directly owns 16,663 shares in the company, valued at $9,333,946.08. The trade was a 1.77 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Michael A. Boxer sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $560.16, for a total value of $1,120,320.00. Following the completion of the sale, the senior vice president now owns 12,736 shares of the company’s stock, valued at $7,134,197.76. This represents a 13.57 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 47,150 shares of company stock valued at $25,954,465. Insiders own 0.34% of the company’s stock.

Analysts Set New Price Targets

TMO has been the topic of a number of research reports. TD Cowen boosted their target price on shares of Thermo Fisher Scientific from $656.00 to $686.00 in a report on Tuesday, October 22nd. Barclays reduced their price objective on Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating for the company in a research note on Wednesday, October 23rd. Wells Fargo & Company reduced their price objective on shares of Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating for the company in a research note on Thursday, October 24th. Stephens assumed coverage on shares of Thermo Fisher Scientific in a report on Tuesday, October 1st. They set an “overweight” rating and a $680.00 price target on the stock. Finally, Bernstein Bank boosted their target price on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the company a “market perform” rating in a research note on Tuesday, October 22nd. Four analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $648.95.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO opened at $572.85 on Wednesday. The business’s 50-day simple moving average is $530.86 and its 200-day simple moving average is $568.96. Thermo Fisher Scientific Inc. has a 52 week low of $493.30 and a 52 week high of $627.88. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63. The firm has a market cap of $219.11 billion, a price-to-earnings ratio of 35.92, a P/E/G ratio of 3.71 and a beta of 0.76.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, topping analysts’ consensus estimates of $5.25 by $0.03. The business had revenue of $10.60 billion during the quarter, compared to analysts’ expectations of $10.63 billion. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. Thermo Fisher Scientific’s revenue for the quarter was up .2% on a year-over-year basis. During the same period in the previous year, the company earned $5.69 earnings per share. As a group, equities research analysts expect that Thermo Fisher Scientific Inc. will post 21.68 earnings per share for the current fiscal year.

Thermo Fisher Scientific announced that its Board of Directors has initiated a stock buyback plan on Friday, November 15th that allows the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization allows the medical research company to reacquire up to 2% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s board of directors believes its stock is undervalued.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th were given a $0.39 dividend. This represents a $1.56 annualized dividend and a dividend yield of 0.27%. The ex-dividend date of this dividend was Friday, December 13th. Thermo Fisher Scientific’s dividend payout ratio is currently 9.78%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.